Kala Pharmaceuticals, Inc. announced the appointment of Andrew I. Koven to the Company’s Board of Directors. Mr. Koven will serve as a Class I director and serve on the Compensation and the Nominating and Corporate Governance committees of the Board of Directors. Mr. Koven has served as President and Chief Business Officer at Aralez Pharmaceuticals Inc. since 2016 and held the same position in 2015 at POZEN Inc., where he was instrumental in negotiating a merger with Tribute Pharmaceuticals Canada Inc. to create Aralez Pharmaceuticals. Prior to joining POZEN, Mr. Koven was Chief Administrative Officer, General Counsel and Corporate Secretary at Auxilium Pharmaceuticals Inc., where he was responsible for legal functions, government affairs and technical operations until it was sold to Endo Pharmaceuticals in 2015. Prior to that, he held roles as Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals Inc., where he oversaw all matters related to legal, quality and compliance, corporate development and licensing and technical operations until it was acquired by Merck in 2011.